Overview
This is the only QPPV Forum designed for QPPVs by QPPVs, now in its 12th year and still going strong. This Forum continues to identify key trends requiring QPPV awareness, input and oversight. This year’s objectives, as shown below, build on past successes and have been shaped by valuable feedback provided by participants of the past eleven meetings, plus many years of QPPV and Regulator interaction at this Forum.
Over time, one of the key successes of the Forum has been the ability to secure continuing support and involvement of key regulators. Sessions have been open and interactive with attendees appreciating opportunities to raise challenging issues in an informal environment. This 12th QPPV Forum continues this successful approach.
Featured
Want to learn more about 2018 European Forum for Qualified Person for Pharmacovigilance (QPPV)? You've come to the right site!
Short Course or Primer
To keep you at the forefront.
Program Committee
-
Elspeth McIntosh, MBA, RN Director
Castle Pharmacovigilance Ltd, United Kingdom -
Margaret Anne Walters Deputy EU Qualified Person for Pharmacovigilance
Merck, Sharp & Dohme Ltd, United Kingdom -
Vicki Edwards, RPh Vice President, Pharmacovigilance Excellence and International QPPV
Abbvie, United Kingdom -
Doris Irene Stenver, MD, MPA Independent Pharmacovigilance Adviser
Unique Advice, Denmark -
Brian Edwards, DrMed Vice President
International Society of Pharmacovigilance, United Kingdom -
Michael Richardson, MD, FFPM, FRCP Senior Vice President, WorldWide Patient Safety
Bristol-Myers Squibb, United Kingdom -
Winrich Rauschning, DrMed, MD, MBA QPPV
Biolitec Pharma, Germany -
Barbara De Bernardi, MD EUQPPV Vice President - Head of Global QPPV Office
Pfizer S.r.l., Italy -
Peter De Veene, MD EU QPPV
Incyte, Belgium -
Anna Louise Van Der Salm, PhD, MSc Director PV, Managing partner
DADA Consultancy B.V., Netherlands -
Magnus Ysander, MD EU & UK QPPV & Head Pharmacovigilance Excellence
AstraZeneca, Sweden
Have an account?